½ÃÀ庸°í¼­
»óǰÄÚµå
1560823

¼¼°èÀÇ º¹¸·Åõ¼® ½ÃÀå(2024-2031³â)

Global Peritoneal Dialysis Market - 2024 - 2031

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: DataM Intelligence | ÆäÀÌÁö Á¤º¸: ¿µ¹® 186 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

º¸°í¼­ °³¿ä

º¹¸·Åõ¼® ¼¼°è ½ÃÀåÀº 2023³â 52¾ï ´Þ·¯¿¡¼­ 2031³â 83¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, ¿¹Ãø ±â°£ÀÎ 22024-2031³â°£ ¿¬Æò±Õ 6.0% ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¹¸·Åõ¼®Àº ½ÅÀåÀÌ Ç÷¾×À» È¿°úÀûÀ¸·Î °É·¯³»Áö ¸øÇÏ´Â ½ÅºÎÀüÁõ Ä¡·á¹ýÀÔ´Ï´Ù. º¹¸·Åõ¼®Àº º¹¸·ÀÌ ÇÊÅÍ ¿ªÇÒÀ» ÇÏ´Â À§ ºÎºÐ(º¹ºÎ)¿¡ Æ©ºê¸¦ ÅëÇØ ¼¼Ã´¾×À» Èê·Áº¸³»´Â °ÍÀÔ´Ï´Ù. ÀÏÁ¤ ½Ã°£ÀÌ Áö³ª¸é ¿©°úµÈ ¾×ü´Â Æó±âµË´Ï´Ù. º¹¸·Åõ¼®Àº ü¿Ü¿¡¼­ Ç÷¾×À» ±â°è·Î ¿©°úÇÏ´Â Ç÷¾× Åõ¼®°ú´Â ´Ù¸¨´Ï´Ù. º¹¸·Åõ¼®Àº Áý, Á÷Àå, ¿©ÇàÁö µî¿¡¼­ ½ÃÇàÇÒ ¼ö ÀÖÁö¸¸, ¸ðµç ½ÅºÎÀü ȯÀÚ°¡ º¹¸·Åõ¼®ÀÇ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ¼º°øÀûÀÎ º¹¸·Åõ¼®À» À§Çؼ­´Â ¼÷·ÃµÈ ¼Õ±æ°ú ½Å·ÚÇÒ ¼ö ÀÖ´Â °£º´ÀÎÀÌ ÇÊ¿äÇÕ´Ï´Ù.

½ÃÀå ¿ªÇÐ :

ÃËÁø¿äÀΰú ¾ïÁ¦¿äÀÎ

¸¸¼º ½ÅÀå ÁúȯÀÇ À¯º´·ü »ó½Â

¼¼°è ESRD ¹× CKD ¹ßº´·ü Áõ°¡´Â ÁÖ¿ä ÃËÁø¿äÀÎ Áß ÇϳªÀÔ´Ï´Ù. Åõ¼®ÀÌ ÇÊ¿äÇÑ È¯ÀÚ°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ä¡·á ¿É¼ÇÀ¸·Î º¹¸·Åõ¼®(PD)¿¡ ´ëÇÑ ¼ö¿äµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, CDC 2023¿¡ µû¸£¸é ¹Ì±¹ ¼ºÀÎÀÇ 14%, 355¾ï ¸íÀÌ ¸¸¼ºÄáÆÏº´(CKD)À» ¾Î°í ÀÖ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖ½À´Ï´Ù. À¯º´·üÀº ¿¬·É, ÀÎÁ¾, ¹ÎÁ·¿¡ µû¶ó ´Ù¸£¸ç, CKD´Â 65¼¼ ÀÌ»ó(34%), ºñÈ÷½ºÆÐ´Ð°è ÈæÀÎ(20%), ¿©¼º(14%)¿¡¼­ ´õ ¸¹ÀÌ ¹ß»ýÇÕ´Ï´Ù. ¶ÇÇÑ ºñ È÷½ºÆÐ´Ð°è ¾Æ½Ã¾Æ°è ¶Ç´Â ¹éÀÎ ¼ºÀο¡¼­ ´õ ÈçÇÕ´Ï´Ù.

¶ÇÇÑ, 2023³â ISN-GKHA º¸°í¼­´Â ¾à 8,500¾ï ¸íÀÌ CKD¸¦ ¾Î°í ÀÖ´Â °ÍÀ¸·Î Ãß»êÇϰí ÀÖ½À´Ï´Ù. ºÒ¸®ÇÑ Ã³Áö¿¡ ÀÖ´Â »ç¶÷µéÀº ´õ ³ôÀº À§Çè¿¡ Ã³ÇØ ÀÖ½À´Ï´Ù.

¼÷·ÃµÈ Àü¹® Àη ºÎÁ·

º¹¸·Åõ¼®(PD) Àåºñ ½ÃÀåÀÇ ¼ºÀåÀº ¾ö°ÝÇÑ Á¤ºÎ ±ÔÁ¦, ±â¼úÀû ½ÇÆÐ Áõ°¡, Å»Àå ¹× Ä«Å×ÅÍ ¸·Èû°ú °°Àº ÇÕº´Áõ, ¼÷·ÃµÈ Àü¹®°¡ ºÎÁ·À¸·Î ÀÎÇØ ¾î·Á¿òÀ» °Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ³ëÀÎÃþÀÇ ³·Àº ¼ö¿ë¼º°ú ÀνÄ, PD »çÀÌŬ¸®½ºÆ®¿¡ ´ëÇÑ ³·Àº ÀÎÁöµµµµ ÇÑ ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

½ÃÀå ¼¼ºÐÈ­ ºÐ¼®

¼¼°è º¹¸·Åõ¼® ½ÃÀåÀº Á¦Ç° À¯Çü, Ä¡·á À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ ¹× Áö¿ªº°·Î ºÐ·ùµË´Ï´Ù.

Á¦Ç° À¯Çüº°·Î´Â º¹¸·Åõ¼®¾×ÀÌ º¹¸·Åõ¼® ½ÃÀå Á¡À¯À²ÀÇ ¾à 43.3%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.

Á¦Ç° À¯Çüº° º¹¸·Åõ¼®¾× Á¡À¯À²Àº ¾à 43.3%¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù. º¹¸·Åõ¼®¾×Àº Åõ¼®¾×À¸·Îµµ ¾Ë·ÁÁ® ÀÖÀ¸¸ç ¸»±â ½ÅºÎÀüÁõ(ESRD) ¹× ÁßÁõ ¸¸¼º ½ÅÀå Áúȯ(CKD) ȯÀÚÀÇ Ä¡·á¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÀüÇØÁú, Æ÷µµ´ç ¹× ±âŸ »ïÅõ¾ÐÁ¦¸¦ Æ÷ÇÔÇÏ´Â ÀÌ Åõ¼®¾×Àº ¹ÝÅõ°ú¼º ÇÊÅÍ ¿ªÇÒÀ» ÇÏ´Â Ä«Å×Å͸¦ ÅëÇØ º¹°­ ³»·Î µµÀԵ˴ϴÙ. Åõ¼®¾×ÀÇ ÁÖ¿ä ¿ªÇÒÀº Ç÷¾×¿¡¼­ ³ëÆó¹°, °úµµÇÑ ¼öºÐ ¹× µ¶¼Ò¸¦ Á¦°ÅÇÏ´Â °ÍÀÔ´Ï´Ù. Åõ¼®¾×ÀÇ Æ÷µµ´ç ³óµµ´Â ü¾× Á¦°Å ¹× ³ëÆó¹° Á¦°Å È¿À²¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù.

¿¹¸¦ µé¾î, 2024³â 3¿ù Àεµ ÇコÄÉ¾î ¾÷°è¿¡¼­ À¯¸íÇÑ ÆÄ¸®´Ù¹Ùµå¿¡ º»»ç¸¦ µÐ ¹ÌÆ®¶ó Àδõ½ºÆ®¸®Áî(Mitra Industries)´Â °ÅÀÇ Áß¼º pH¿Í ³·Àº Æ÷µµ´ç ºÐÇØ »ê¹°(GDP)À» °¡Áø 3½Ç ±¸Á¶ÀÇ º¹¸·Åõ¼®(PD) ¹éÀ» ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ È¹±âÀûÀÎ Á¦Ç°Àº ¸¸¼ºÄáÆÏº´(CKD) ȯÀڵ鿡°Ô Áß¿äÇÑ Ä¡·á¹ýÀÎ º¹¸·Åõ¼®À» ¹Þ´Â ȯÀÚµéÀÇ Ä¡·á¿¡ Çõ¸íÀ» ÀÏÀ¸Å°±â À§ÇÑ °ÍÀÔ´Ï´Ù.

Áö¿ªº° ½ÃÀå ºÐ¼®

ºÏ¹Ì´Â ¿¹Ãø ±â°£ µ¿¾È Àüü ½ÃÀå Á¡À¯À²ÀÇ ¾à 38.4%¸¦ Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù.

ºÏ¹Ì´Â ½ÅºÎÀü ¹× ¸¸¼º ½ÅÀå ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ´õºÒ¾î ÀÇ·áºñ Áõ°¡, Á¤ºÎÀÇ ÀÌ´Ï¼ÅÆ¼ºê, °¡Ã³ºÐ ¼ÒµæÀÌ »ê¾÷ ¼ºÀå¿¡ ±â¿©Çϸ鼭 ¿¹Ãø ±â°£ µ¿¾È Àüü ½ÃÀå¿¡¼­ ¾à 38.4%ÀÇ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ÃßÁ¤ ¹× ¿¹ÃøµË´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´°ú ºñ¸¸Àº ½ÅÀå ÁúȯÀÇ ¿øÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, ±¹¸³´ç´¢º´ ¹× ¼ÒÈ­±â ½ÅÀ庴 ¿¬±¸¼Ò¿¡ µû¸£¸é ¹Ì±¹ ¼ºÀÎ 7¸í Áß 1¸í ÀÌ»ó, ¾à 370¾ï ¸í Áß 1¸íÀÌ ¸¸¼º ½ÅÀ庴(CKD)À» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µË´Ï´Ù. ½ÅÀå ÁúȯÀ» À¯¹ßÇÏ´Â ´Ù¸¥ À§Çè ¿äÀÎÀ¸·Î´Â ½ÉÀ庴°ú ½ÅºÎÀüÁõÀÇ °¡Á··Â µîÀÌ ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú Á¶»ç ¹üÀ§

Á¦2Àå Á¤ÀÇ¿Í °³¿ä

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå ¿ªÇÐ

  • ¿µÇâ¿äÀÎ
    • ¼ºÀå ÃËÁø¿äÀÎ
    • ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ±âȸ
    • ¿µÇ⠺м®

Á¦5Àå »ê¾÷ ºÐ¼®

  • PorterÀÇ Five Forces ºÐ¼®
  • °ø±Þ¸Á ºÐ¼®
  • °¡°Ý ºÐ¼®
  • ±ÔÁ¦ ºÐ¼®
  • ƯÇ㠺м®
  • PESTLE ºÐ¼®
  • SWOT ºÐ¼®
  • DMI Àǰß

Á¦6Àå Á¦Ç° À¯Çüº°

  • º¹¸·Åõ¼® ¼Ö·ç¼Ç
  • º¹¸·Åõ¼® Àåºñ
  • º¹¸·Åõ¼® Ä«Å×ÅÍ
  • Åõ¼® ¼¼Æ®
  • ±âŸ

Á¦7Àå Ä¡·á À¯Çüº°

  • APD
  • CAPD

Á¦8Àå ÃÖÁ¾»ç¿ëÀÚº°

  • ÀçÅÃÄ¡·á
  • º´¿ø
  • ±âŸ

Á¦9Àå Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ³²¹Ì
    • ºê¶óÁú
    • ¾Æ¸£ÇîÆ¼³ª
    • ±âŸ ³²¹Ì
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • Áß±¹
    • Àεµ
    • ÀϺ»
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦10Àå °æÀï ±¸µµ

  • °æÀï ½Ã³ª¸®¿À
  • ½ÃÀå ÇöȲ/Á¡À¯À² ºÐ¼®
  • ÀμöÇÕº´(M&A) ºÐ¼®

Á¦11Àå ±â¾÷ °³¿ä

  • Baxter International Inc
    • ±â¾÷ °³¿ä
    • Á¦Ç° Æ÷Æ®Æú¸®¿À¿Í ¼³¸í
    • À繫 °³¿ä
    • ÁÖ¿ä ¹ßÀü
  • Fresenius Medical Care AG & Co. KGaA
  • Medtronic plc
  • Nipro Corporation
  • DaVita Inc.
  • Diaverum
  • B. Braun Melsungen AG
  • Asahi Kasei Corporation
  • Huaren Pharmaceutical Co., Ltd.
  • NxStage Medical, Inc

Á¦12Àå ºÎ·Ï

LSH 24.10.14

Report Overview

Global Peritoneal Dialysis Market reached US$ 5.2 billion in 2023 and is expected to reach US$ 8.3 billion by 2031, growing at a CAGR of 6.0% during the forecast period 2024-2031

Peritoneal dialysis is a treatment for kidney failure, where the kidneys cannot filter blood effectively. It involves a cleansing fluid flowing through a tube into the stomach area, or abdomen, where the peritoneum acts as a filter. After a set time, the filtered fluid is discarded. Peritoneal dialysis differs from hemodialysis, which filters blood outside the body in a machine. Treatments can be done at home, work, or while traveling, but not everyone with kidney failure can benefit from this treatment. Skilled hand care and a trusted caregiver are required for successful peritoneal dialysis.

Market Dynamics: Drivers & Restraints

Rise in the prevalence of chronic kidney diseases

The rising incidence of ESRD and CKD worldwide is one of the primary drivers. As the number of patients requiring dialysis grows, the demand for peritoneal dialysis (PD) as a treatment option also increases.

For instance, according to the CDC 2023, reports that 14% of US adults, or 35.5 billion people, have chronic kidney disease (CKD). The prevalence varies by age, race, and ethnicity. CKD is more common in those aged 65 or older (34%), non-Hispanic Black adults (20%), and women (14%). It is also more prevalent in non-Hispanic Asian or White adults.

Moreover, the 2023 ISN-GKHA report estimates that approximately 850 billion people are affected by CKD. People from disadvantaged populations are at higher risk.

Lack of skilled professionals

The market growth of peritoneal dialysis (PD) devices is hindered by stringent government regulations, increasing technical failures, complications like hernias and catheter blockages, and a lack of skilled professionals. Additionally, low acceptance and awareness among the senior population and low awareness of PD cyclers are also contributing factors.

Market Segment Analysis

The global peritoneal dialysis market is segmented based on product type, treatment type, end user, and region.

The peritoneal dialysis solutions from the product type segment accounted for approximately 43.3% of the peritoneal dialysis market share

The peritoneal dialysis solutions from the product type segment accounted for approximately 43.3%. Peritoneal dialysis solutions, also known as dialysates, are essential in treating patients with end-stage renal disease (ESRD) or severe chronic kidney disease (CKD). These fluids, containing electrolytes, glucose, and other osmotic agents, are introduced into the peritoneal cavity through a catheter, acting as a semi-permeable filter. The primary function of the dialysis solution is to draw waste products, excess fluids, and toxins from the blood. The concentration of glucose in the solution significantly influences fluid removal and waste clearance efficiency.

For instance, in March 2024, Faridabad-based Mitra Industries, a renowned name in India's healthcare industry, unveiled its latest innovation- a triple-chambered peritoneal dialysis (PD) bag with a near-neutral pH and low glucose degradation products (GDPs). This groundbreaking product aims to revolutionize patient care for those undergoing peritoneal dialysis, a crucial therapy for Chronic Kidney Disease (CKD) patients.

Market Geographical Analysis

North America is estimated to hold about 38.4% of the total market share throughout the forecast period

North America is estimated to hold about 38.4% of the total market share throughout the forecast period due to the increasing prevalence of kidney failures and chronic kidney diseases, along with rising healthcare costs, government efforts, and disposable income, contribute to the growth of the industry. Additionally, diabetes and obesity contribute to kidney disorders.

For instance, according to National Institute of Diabetes and Digestive Kidney Diseases, Chronic kidney disease (CKD) affects more than 1 in 7 U.S. adults-an estimated 37 billion Americans.1 For Americans with diabetes or high blood pressure-the two most common causes of kidney disease-the risk for CKD is even greater. Nearly 1 in 3 people with diabetes and 1 in 5 people with high blood pressure have kidney disease.1 Other risk factors for developing kidney disease include heart disease and a family history of kidney failure.

Market Segmentation

By Product Type

Peritoneal Dialysis Solutions

Peritoneal Dialysis Machines

Peritoneal Dialysis Catheters

Dialysis Sets

Others

By Treatment Type

Automated Peritoneal Dialysis (APD)

Continuous Ambulatory Peritoneal Dialysis (CAPD)

By End User

Homecare Settings

Hospitals

Others

By Region

North America

U.S.

Canada

Mexico

Europe

Germany

UK

France

Italy

Spain

Rest of Europe

South America

Brazil

Argentina

Rest of South America

Asia-Pacific

China

India

Japan

South Korea

Rest of Asia-Pacific

Middle East and Africa

Market Competitive Landscape

The major global players in the market include Baxter International Inc, Fresenius Medical Care AG & Co. KGaA, Medtronic plc, Nipro Corporation, DaVita Inc., Diaverum, B. Braun Melsungen AG, Asahi Kasei Corporation, Huaren Pharmaceutical, Co., Ltd, NxStage Medical, Inc among others.

Key Developments

In June 2023, AWAK Technologies (AWAK) and Singapore General Hospital (SGH) announced the launch of a pre-pivotal clinical trial with the enrolment of their first subject to study the safety and efficacy of an improved Automated Wearable Artificial Kidney Peritoneal Dialysis (AWAK PD) device. AWAK PD is a wearable and ultra-portable peritoneal dialysis (PD) system that allows patients with end-stage kidney disease to have dialysis on the go and has been granted 'Breakthrough Device Designation' by the US Food and Drug Administration (FDA).

Why Purchase the Report?

To visualize the global peritoneal dialysis market segmentation based on product type, treatment type, end user, and region as well as understand key commercial assets and players.

Identify commercial opportunities by analyzing trends and co-development.

Excel data sheet with numerous data points of the peritoneal dialysis market level with all segments.

PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.

Product mapping available as excel consisting of key products of all the major players.

The global peritoneal dialysis market report would provide approximately 64 tables, 61 figures, and 186 pages.

Target Audience 2024

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Product Type
  • 3.2. Snippet by Treatment Type
  • 3.3. Snippet by End User
  • 3.4. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Rise in the prevalence of chronic kidney diseases
      • 4.1.1.2. Rise in the advancements of devices
    • 4.1.2. Restraints
      • 4.1.2.1. Lack of skilled professionals
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's Five Force Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Patent Analysis
  • 5.6. PESTLE Analysis
  • 5.7. SWOT Analysis
  • 5.8. DMI Opinion

6. By Product Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 6.1.2. Market Attractiveness Index, By Product Type
  • 6.2. Peritoneal Dialysis Solutions*
    • 6.2.1. Introduction
  • 6.3. Peritoneal Dialysis Machines
  • 6.4. Peritoneal Dialysis Catheters
  • 6.5. Dialysis Sets
  • 6.6. Others

7. By Treatment Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 7.1.2. Market Attractiveness Index, By Treatment Type
  • 7.2. Automated Peritoneal Dialysis (APD)*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Continuous Ambulatory Peritoneal Dialysis (CAPD)

8. By End User

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 8.1.2. Market Attractiveness Index, By End User
  • 8.2. Homecare Settings*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Hospitals
  • 8.4. Others

9. By Region

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 9.1.2. Market Attractiveness Index, By Region
  • 9.2. North America
    • 9.2.1. Introduction
    • 9.2.2. Key Region-Specific Dynamics
    • 9.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.2.6.1. U.S.
      • 9.2.6.2. Canada
      • 9.2.6.3. Mexico
  • 9.3. Europe
    • 9.3.1. Introduction
    • 9.3.2. Key Region-Specific Dynamics
    • 9.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.3.6.1. Germany
      • 9.3.6.2. UK
      • 9.3.6.3. France
      • 9.3.6.4. Italy
      • 9.3.6.5. Spain
      • 9.3.6.6. Rest of Europe
  • 9.4. South America
    • 9.4.1. Introduction
    • 9.4.2. Key Region-Specific Dynamics
    • 9.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.4.6.1. Brazil
      • 9.4.6.2. Argentina
      • 9.4.6.3. Rest of South America
  • 9.5. Asia-Pacific
    • 9.5.1. Introduction
    • 9.5.2. Key Region-Specific Dynamics
    • 9.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
    • 9.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 9.5.6.1. China
      • 9.5.6.2. India
      • 9.5.6.3. Japan
      • 9.5.6.4. South Korea
      • 9.5.6.5. Rest of Asia-Pacific
  • 9.6. Middle East and Africa
    • 9.6.1. Introduction
    • 9.6.2. Key Region-Specific Dynamics
    • 9.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 9.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
    • 9.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User

10. Competitive Landscape

  • 10.1. Competitive Scenario
  • 10.2. Market Positioning/Share Analysis
  • 10.3. Mergers and Acquisitions Analysis

11. Company Profiles

  • 11.1. Baxter International Inc*
    • 11.1.1. Company Overview
    • 11.1.2. Product Portfolio and Description
    • 11.1.3. Financial Overview
    • 11.1.4. Key Developments
  • 11.2. Fresenius Medical Care AG & Co. KGaA
  • 11.3. Medtronic plc
  • 11.4. Nipro Corporation
  • 11.5. DaVita Inc.
  • 11.6. Diaverum
  • 11.7. B. Braun Melsungen AG
  • 11.8. Asahi Kasei Corporation
  • 11.9. Huaren Pharmaceutical Co., Ltd.
  • 11.10. NxStage Medical, Inc (*LIST NOT EXHAUSTIVE)

12. Appendix

  • 12.1. About Us and Services
  • 12.2. Contact Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦